Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $53,030,564.60. This trade represents a 1.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00.
- On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.19, for a total value of $691,900.00.
- On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $71.75, for a total value of $1,435,000.00.
- On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.50, for a total value of $635,000.00.
- On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00.
Halozyme Therapeutics Stock Performance
Halozyme Therapeutics stock opened at $71.60 on Friday. The stock has a fifty day moving average price of $66.63 and a 200 day moving average price of $68.72. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22. The firm has a market capitalization of $8.49 billion, a P/E ratio of 25.76, a PEG ratio of 0.29 and a beta of 0.88. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.
Analysts Set New Price Targets
A number of equities analysts have recently commented on HALO shares. HC Wainwright raised their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. UBS Group reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $81.60.
View Our Latest Stock Analysis on HALO
Halozyme Therapeutics News Summary
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: Zacks Research raised earnings forecasts for multiple future periods, including FY2026, FY2027, and FY2028, which strengthens the long-term growth story for Halozyme Therapeutics. Halozyme Therapeutics article
- Positive Sentiment: Analysts also increased estimates for several 2027 quarters, including Q1, Q2, Q3, and Q4, suggesting improving earnings momentum. Halozyme Therapeutics article
- Neutral Sentiment: Some near-term and farther-out estimates were mixed, with a slight cut to Q2 2026 and a reduction in Q1 2028, indicating the outlook improved overall but not across every period. Halozyme Therapeutics article
- Neutral Sentiment: Recent insider sales by the CEO and a director were disclosed, but both were made under pre-arranged 10b5-1 trading plans, which typically makes them less alarming to investors. Halozyme Therapeutics article
Hedge Funds Weigh In On Halozyme Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Measured Wealth Private Client Group LLC raised its stake in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the period. Larson Financial Group LLC boosted its holdings in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. Clearstead Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the last quarter. Harbour Investments Inc. grew its position in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 372 shares in the last quarter. Finally, Penserra Capital Management LLC bought a new stake in shares of Halozyme Therapeutics in the third quarter worth $52,000. 97.79% of the stock is owned by institutional investors and hedge funds.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
